PubRank

Charles Antzelevitch

Author PubWeight™ 252.74‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006 9.44
2 An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 2009 4.99
3 Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 2002 3.76
4 Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2003 3.68
5 Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes? Circulation 2003 3.05
6 Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007 2.90
7 Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm 2010 2.79
8 Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation 2003 2.74
9 The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol 2010 2.56
10 Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave. Heart Rhythm 2007 2.44
11 Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008 2.42
12 Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med 2008 2.38
13 Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm 2011 2.26
14 Fever-induced Brugada pattern: how common is it and what does it mean? Heart Rhythm 2013 2.25
15 Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002 2.23
16 The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell 2005 2.19
17 Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. Circ Arrhythm Electrophysiol 2009 2.16
18 Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 2002 2.16
19 Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle. Am J Physiol Heart Circ Physiol 2003 2.12
20 Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm 2004 2.07
21 Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004 2.05
22 Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 2006 2.03
23 Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm 2011 2.01
24 A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. Cardiovasc Res 2008 2.01
25 Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003 1.97
26 Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm 2008 1.96
27 Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm 2006 1.91
28 Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 2002 1.91
29 Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 2004 1.88
30 Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm 2011 1.87
31 A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet 2009 1.87
32 Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 2004 1.87
33 Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet 2013 1.86
34 Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation 2004 1.86
35 Cellular basis for the monophasic action potential. Which electrode is the recording electrode? Cardiovasc Res 2004 1.85
36 Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation 2002 1.84
37 Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm 2005 1.83
38 Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 2006 1.78
39 The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol 2010 1.78
40 Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol 2009 1.78
41 Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol 2005 1.74
42 Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7). Heart Rhythm 2006 1.74
43 Phenotypic characterization of a large European family with Brugada syndrome displaying a sudden unexpected death syndrome mutation in SCN5A:. J Cardiovasc Electrophysiol 2004 1.69
44 Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm 2008 1.69
45 Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome. Eur Heart J 2005 1.61
46 Brugada-like syndrome in infancy presenting with rapid ventricular tachycardia and intraventricular conduction delay. Circulation 2011 1.60
47 Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol 2006 1.60
48 A novel mutation in the HCN4 gene causes symptomatic sinus bradycardia in Moroccan Jews. J Cardiovasc Electrophysiol 2010 1.60
49 Early repolarization syndrome: a decade of progress. J Electrocardiol 2013 1.59
50 AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog. J Cardiovasc Pharmacol 2010 1.57
51 Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm 2006 1.56
52 Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations. J Am Coll Cardiol 2011 1.55
53 Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/Ito block. Am J Physiol Heart Circ Physiol 2004 1.53
54 Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy. Heart Rhythm 2009 1.51
55 Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 2003 1.51
56 Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation 2005 1.50
57 Functional expression of "cardiac-type" Nav1.5 sodium channel in canine intracardiac ganglia. Heart Rhythm 2006 1.50
58 Fever and Brugada syndrome. Pacing Clin Electrophysiol 2002 1.48
59 Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008 1.46
60 Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant. Heart Rhythm 2012 1.46
61 Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm 2011 1.46
62 Resolving the M-cell debate: why and how. Heart Rhythm 2011 1.45
63 Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. Heart Rhythm 2011 1.44
64 A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents. Heart Rhythm 2011 1.43
65 KCNE2 modulation of Kv4.3 current and its potential role in fatal rhythm disorders. Heart Rhythm 2009 1.43
66 Is a narrow and tall QRS complex an ECG marker for sudden death? Heart Rhythm 2008 1.42
67 Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing. Circulation 2004 1.39
68 Mode of onset of ventricular fibrillation in patients with early repolarization pattern vs. Brugada syndrome. Eur Heart J 2009 1.38
69 Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J 2011 1.37
70 Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol 2004 1.35
71 Cellular and subcellular alternans in the canine left ventricle. Am J Physiol Heart Circ Physiol 2007 1.32
72 Cellular basis for ST-segment changes observed during ischemia. J Electrocardiol 2003 1.31
73 Can inhibition of IKur promote atrial fibrillation? Heart Rhythm 2008 1.31
74 Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf 2008 1.30
75 Occurrence of "J waves" in 12-lead ECG as a marker of acute ischemia and their cellular basis. Pacing Clin Electrophysiol 2007 1.28
76 Gain of function in IKs secondary to a mutation in KCNE5 associated with atrial fibrillation. Heart Rhythm 2008 1.27
77 Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol 2010 1.27
78 New developments in atrial antiarrhythmic drug therapy. Nat Rev Cardiol 2010 1.27
79 Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm 2007 1.27
80 Does Tpeak-Tend provide an index of transmural dispersion of repolarization? Heart Rhythm 2007 1.23
81 Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr). PLoS One 2012 1.23
82 Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol 2010 1.21
83 The role of local voltage potentials in outflow tract ectopy. Europace 2010 1.20
84 Atrial-selective sodium channel blockers: do they exist? J Cardiovasc Pharmacol 2008 1.18
85 M cells in the human heart. Circ Res 2010 1.17
86 Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation 2006 1.16
87 Potential proarrhythmic effects of biventricular pacing. J Am Coll Cardiol 2005 1.15
88 Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc Res 2007 1.15
89 Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation 2004 1.14
90 Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol 2009 1.13
91 Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs 2009 1.12
92 Accelerated inactivation of the L-type calcium current due to a mutation in CACNB2b underlies Brugada syndrome. J Mol Cell Cardiol 2009 1.11
93 Long QT, syndactyly, joint contractures, stroke and novel CACNA1C mutation: expanding the spectrum of Timothy syndrome. Am J Med Genet A 2011 1.11
94 Short QT syndrome. Genotype-phenotype correlations. J Electrocardiol 2005 1.11
95 Prominent I(Ks) in epicardium and endocardium contributes to development of transmural dispersion of repolarization but protects against development of early afterdepolarizations. J Cardiovasc Electrophysiol 2002 1.10
96 HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. J Cardiovasc Pharmacol 2003 1.09
97 Pharmacological approach to the treatment of long and short QT syndromes. Pharmacol Ther 2008 1.09
98 The Brugada syndrome: is an implantable cardioverter defibrillator the only therapeutic option? Pacing Clin Electrophysiol 2002 1.08
99 Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block. Am J Physiol Heart Circ Physiol 2011 1.08
100 Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. Circulation 2006 1.08
101 Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry. Heart Rhythm 2008 1.07
102 Cellular and ionic basis for the sex-related difference in the manifestation of the Brugada syndrome and progressive conduction disease phenotypes. J Electrocardiol 2003 1.05
103 Late potentials and the Brugada syndrome. J Am Coll Cardiol 2002 1.05
104 Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome. Curr Pharm Des 2005 1.04
105 A common single nucleotide polymorphism can exacerbate long-QT type 2 syndrome leading to sudden infant death. Circ Cardiovasc Genet 2010 1.04
106 Novel mutation in the SCN5A gene associated with arrhythmic storm development during acute myocardial infarction. Heart Rhythm 2007 1.04
107 The arrhythmogenic consequences of increasing late INa in the cardiomyocyte. Cardiovasc Res 2013 1.03
108 New pharmacological strategies for the treatment of atrial fibrillation. Ann Noninvasive Electrocardiol 2009 1.02
109 ECG phenomenon of idiopathic and paradoxical short QT intervals. Card Electrophysiol Rev 2002 1.01
110 Optical and electrical recordings from isolated coronary-perfused ventricular wedge preparations. J Mol Cell Cardiol 2012 1.01
111 Lidocaine-induced Brugada syndrome phenotype linked to a novel double mutation in the cardiac sodium channel. Circ Res 2008 1.00
112 Genetic basis of Brugada syndrome. Heart Rhythm 2007 1.00
113 Role of repolarization restitution in the development of coarse and fine atrial fibrillation in the isolated canine right atria. J Cardiovasc Electrophysiol 2005 0.99
114 Fever accentuates transmural dispersion of repolarization and facilitates development of early afterdepolarizations and torsade de pointes under long-QT Conditions. Circ Arrhythm Electrophysiol 2008 0.99
115 Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation. Ann N Y Acad Sci 2008 0.97
116 American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. Circulation 2011 0.97
117 Differential effects of the transient outward K(+) current activator NS5806 in the canine left ventricle. J Mol Cell Cardiol 2009 0.96
118 Effect of Wenxin Keli and quinidine to suppress arrhythmogenesis in an experimental model of Brugada syndrome. Heart Rhythm 2013 0.96
119 Extracellular proton depression of peak and late Na⁺ current in the canine left ventricle. Am J Physiol Heart Circ Physiol 2011 0.95
120 Link between hypothermia and the Brugada syndrome. J Cardiovasc Electrophysiol 2004 0.95
121 Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: II. Insights from a mathematical model. Am J Physiol Heart Circ Physiol 2011 0.94
122 Novel mutations in domain I of SCN5A cause Brugada syndrome. Mol Genet Metab 2002 0.94
123 Dual variation in SCN5A and CACNB2b underlies the development of cardiac conduction disease without Brugada syndrome. Pacing Clin Electrophysiol 2009 0.94
124 Physiological consequences of transient outward K+ current activation during heart failure in the canine left ventricle. J Mol Cell Cardiol 2012 0.94
125 Novel mutations in the KCND3-encoded Kv4.3 K+ channel associated with autopsy-negative sudden unexplained death. Hum Mutat 2012 0.93
126 Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967. Heart Rhythm 2013 0.92
127 Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm 2008 0.92
128 Ischemic ventricular arrhythmias: experimental models and their clinical relevance. Heart Rhythm 2011 0.91
129 Transseptal dispersion of repolarization and its role in the development of Torsade de Pointes arrhythmias. J Cardiovasc Electrophysiol 2009 0.90
130 The Contribution of HCN4 to normal sinus node function in humans and animal models. Pacing Clin Electrophysiol 2009 0.90
131 Brugada syndrome and ischemia-induced ST-segment elevation. Similarities and differences. J Electrocardiol 2005 0.90
132 How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation? J Atr Fibrillation 2008 0.90
133 Atrial fibrillation and Brugada syndrome. J Am Coll Cardiol 2008 0.89
134 Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine. Circ Arrhythm Electrophysiol 2012 0.89
135 Role of late sodium channel current block in the management of atrial fibrillation. Cardiovasc Drugs Ther 2013 0.89
136 Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. Circ Arrhythm Electrophysiol 2014 0.88
137 Unraveling the Enigma of Bangungut: Is Sudden Unexplained Nocturnal Death Syndrome (SUNDS) in the Philippines a Disease Allelic to the Brugada Syndrome? Philipp J Intern Med 2011 0.88
138 Genetic predisposition and cellular basis for ischemia-induced ST-segment changes and arrhythmias. J Electrocardiol 2007 0.88
139 Cellular mechanism and arrhythmogenic potential of T-wave alternans in the Brugada syndrome. J Cardiovasc Electrophysiol 2007 0.88
140 Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circ Arrhythm Electrophysiol 2012 0.88
141 Brugada Syndrome: Clinical, Genetic, Molecular, Cellular, and Ionic Aspects. Curr Probl Cardiol 2015 0.86
142 Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone. J Pharmacol Exp Ther 2011 0.86
143 The cardiologists' worst nightmare sudden death from "benign" ventricular arrhythmias. J Am Coll Cardiol 2005 0.86
144 A novel mutation in KCNQ1 associated with a potent dominant negative effect as the basis for the LQT1 form of the long QT syndrome. J Cardiovasc Electrophysiol 2007 0.86
145 Androgens and male predominance of the Brugada syndrome phenotype. Pacing Clin Electrophysiol 2003 0.86
146 Comparison of the effects of a transient outward potassium channel activator on currents recorded from atrial and ventricular cardiomyocytes. J Cardiovasc Electrophysiol 2011 0.86
147 Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol 2010 0.85
148 Brugada syndrome. Int J Cardiol 2005 0.85
149 Identification of specific pluripotent stem cell death--inducing small molecules by chemical screening. Stem Cell Rev 2012 0.84
150 Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac voltage-dependent L-type calcium channel. Circ Res 2011 0.84
151 A complete right bundle-branch block masking Brugada syndrome. J Electrocardiol 2012 0.84
152 Tissue-specific effects of acetylcholine in the canine heart. Am J Physiol Heart Circ Physiol 2013 0.84
153 Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. Heart Rhythm 2010 0.84
154 When u say "U Waves," what do u mean? Pacing Clin Electrophysiol 2004 0.83
155 Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther 2011 0.83
156 Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm 2012 0.83
157 Ionic and cellular mechanisms underlying the development of acquired Brugada syndrome in patients treated with antidepressants. J Cardiovasc Electrophysiol 2011 0.82
158 Extending the conditions of application of an inversion of the Hodgkin-Huxley gating model. Bull Math Biol 2013 0.82
159 Identification and characterization of a transient outward K+ current in human induced pluripotent stem cell-derived cardiomyocytes. J Mol Cell Cardiol 2013 0.82
160 Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves. J Pharmacol Exp Ther 2010 0.81
161 Quinidine: a valuable medication joins the list of 'endangered species'. Europace 2007 0.81
162 Molecular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 2002 0.80
163 Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome. Heart Rhythm 2013 0.80
164 In vivo human demonstration of phase 2 reentry. Heart Rhythm 2005 0.80
165 The acquired Brugada syndrome and the paradox of choice. Heart Rhythm 2009 0.79
166 A temporal window of vulnerability for development of atrial fibrillation with advancing heart failure. Eur J Heart Fail 2014 0.79
167 Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry. Circ Cardiovasc Genet 2010 0.79
168 Modulation of canine cardiac sodium current by Apelin. J Mol Cell Cardiol 2009 0.79
169 Electrophysiologic characteristics and pharmacologic response of human cardiomyocytes isolated from a patient with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2013 0.78
170 Congenital short QT syndrome. Indian Pacing Electrophysiol J 2004 0.78
171 The phenomenon of "QT stunning": the abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm 2012 0.78
172 LQT5 masquerading as LQT2: a dominant negative effect of KCNE1-D85N rare polymorphism on KCNH2 current. Europace 2011 0.78
173 Risk stratification [corrected] of Brugada syndrome revisited. Isr Med Assoc J 2008 0.78
174 Identification of a novel de novo mutation associated with PRKAG2 cardiac syndrome and early onset of heart failure. PLoS One 2013 0.78
175 Is there an overlap between Brugada syndrome and arrhythmogenic right ventricular cardiomyopathy/dysplasia? J Electrocardiol 2005 0.77
176 Overlapping LQT1 and LQT2 phenotype in a patient with long QT syndrome associated with loss-of-function variations in KCNQ1 and KCNH2. Can J Physiol Pharmacol 2010 0.77
177 Study of the extent of the information of cardiologists from São Paulo city, Brazil, regarding a low-prevalence entity: Brugada syndrome. Ann Noninvasive Electrocardiol 2008 0.77
178 A gain-of-function I(K-ATP) mutation and its role in sudden cardiac death associated with J-wave syndromes. Heart Rhythm 2010 0.77
179 Development of a coronary-perfused interventricular septal preparation as a model for studying the role of the septum in arrhythmogenesis. J Electrocardiol 2007 0.77
180 Ventricular fibrillation associated with complete right bundle branch block. Heart Rhythm 2013 0.77
181 Developmental changes in expression and biophysics of ion channels in the canine ventricle. J Mol Cell Cardiol 2013 0.77
182 The J Wave Syndromes and their Role in Sudden Cardiac Death. Card Electrophysiol Clin 2011 0.76
183 Cardiomyocyte calcium cycling in a naturally occurring German shepherd dog model of inherited ventricular arrhythmia and sudden cardiac death. J Vet Cardiol 2013 0.75
184 Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation. Future Cardiol 2011 0.75
185 Brugada-like electrocardiographic pattern. Indian Pacing Electrophysiol J 2003 0.75
186 Multiple arrhythmic syndromes in a newborn, owing to a novel mutation in SCN5A. Can J Physiol Pharmacol 2011 0.75
187 Genetics and Sinus Node Dysfunction. J Atr Fibrillation 2009 0.75
188 Author's response to letter to the editor from Perez and Froelicher. J Electrocardiol 2013 0.75
189 Case scenario: anesthesia-related cardiac arrest in a child with Timothy syndrome. Anesthesiology 2012 0.75
190 Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity. J Cardiovasc Pharmacol 2012 0.75
191 Advances in the Pharmacological Treatment of Atrial Fibrillation. Curr Med Lit Cardiol 2010 0.75
192 Cellular mechanisms underlying the long QT syndrome. J Cardiovasc Electrophysiol 2003 0.75
193 Brugada syndrome: 12 years of progression. Acta Med Okayama 2004 0.75
194 Advances in the Pharmacologic Management of Atrial Fibrillation. Card Electrophysiol Clin 2011 0.75
195 The Brugada syndrome. Curr Opin Cardiol 2002 0.75